Table II.
Associations between BMI category and earlier drug discontinuation.
| Methotrexate | TNFi | Prednisone | HCQ | SSZ | |
|---|---|---|---|---|---|
| n=15,082 | n=8,412 | n=11,627 | n=7,490 | n=4,359 | |
| Discontinued: 14,770 | Discontinued: 8,313 | Discontinued: 11,349 | Discontinue: 7,287 | Discontinued: 4,299 | |
| Partially-adjusted† | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| BMI Category <20 kg/m2 | 1.14 (1.02, 1.27)** | 1.13 (0.96, 1.33) | 0.96 (0.85, 1.07) | 1.12 (0.96, 1.30) | 1.00 (0.81, 1.24) |
| 20–25 kg/m2 | 1.02 (0.97, 1.07) | 1.13 (1.06, 1.21)*** | 0.92 (0.87, 0.97)** | 1.09 (1.02, 1.16)** | 1.06 (0.97, 1.16) |
| 25–30 kg/m2 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 30–35 kg/m2 | 1.00 (0.96, 1.05) | 1.03 (0.98, 1.10) | 1.03 (0.98, 1.08) | 0.95 (0.89, 1.02) | 0.96 (0.89, 1.04) |
| ≥35 kg/m2 | 1.06 (1.00, 1.11)* | 1.07 (1.00, 1.14)* | 1.10 (1.04, 1.17)*** | 0.92 (0.85, 0.99)* | 0.96 (0.88, 1.06) |
| Fully-adjusted‡ | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| BMI Category <20 kg/m2 | 1.13 (1.01, 1.26)*** | 1.18 (1.00, 1.39) | 0.95 (0.84, 1.06) | 1.10 (0.94, 1.29) | 0.98 (0.79, 1.22) |
| 20–25 kg/m2 | 1.04 (0.99, 1.09)* | 1.14 (1.07, 1.22)*** | 0.93 (0.88, 0.98)* | 1.08 (1.01, 1.16)** | 1.06 (0.97, 1.16) |
| 25–30 kg/m2 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 30–35 kg/m2 | 0.99 (0.94, 1.03) | 1.02 (0.97, 1.09) | 1.03 (0.98, 1.08) | 0.97 (0.91, 1.03) | 0.97 (0.89, 1.05) |
| ≥35 kg/m2 | 1.01 (0.96, 1.07) | 1.04 (0.97, 1.11) | 1.11 (1.04, 1.18)*** | 0.95 (0.88, 1.02) | 0.97 (0.88, 1.06) |
*
p<0.05
**
p<0.01
***
p<0.001
†
Adjusted for calendar date, age, sex, black race. For TNFi: also adjusted for drug name and initial vs. subsequent biologic course.
‡
Also adjusted for: Concurrent medication use (HCQ, SSZ, MTX, prednisone, TNFi), RDCI, CRP, ever ACPA-positive, disease duration >5 years, diabetes, HTN, CHF, cancer, anxiety, depression, current smoking. For TNFi: also adjusted for first biologic use and therapy.
BMI: body mass index; HR: hazard ratio; TNFi: tumour necrosis factor inhibitor; RDCI: Rheumatic Disease Comorbidity Index; CRP: C-reactive protein; ACPA: anti-citrullinated peptide antibody; HTN: hypertension; CHF: congestive heart failure.